314. Six Months Follow up of Patients with Guillain-Barré Associated to Zika Virus Infection
Session: Poster Abstract Session: Global Infections
Thursday, October 5, 2017
Room: Poster Hall CD
Posters
  • Zika GB clinical evolution IDweek 2017.pdf (113.8 kB)
  • Background: Increasing data has shown the relationship between Zika Virus (ZIKV) and neurological complications. However, there are still uncertainties about the prognosis of these complications. The aim of this study is to show the neurological characteristics of patients six months after a Guillain-Barré episode related to ZIV infection.

    Methods: Patients with a Guillain-Barré episode were identified prospectively at 5 intensive care units in an endemic zone in Colombia (Valledupar, near the Caribbean coast of Colombia). Brighton´s criteria for Guillain-Barré case definition were used to classify the patients. Clinical data from the clinical records was used. Patients with a positive Zika serology were followed after six months.

    Results: Of 25 patients wirh a diagnosis of Guillain Barré, 20 had a serological study for ZIKV and it was positive in 19 patients (95%). 75% of the cases were men, the median age was 45 years-old and they had a median length of stay of 25 days. 68% hada a febrile syndrome in the 7 to 14 days prior to hospitalization. Median time between fever and neurological symptoms was 9 days. Incapacity to walk was found in 100%, dysphagia in 55% and respiratory insufficiency in 55%. Patients were treated with immunoglobulin or plasmapheresis. Median time to follow up was 193 days in 15 patients. Cuadriparesia was found in 44%, difficulty to walk in 31%, unilateral facial palsy in 19%, and bilateral in 6%. Dysphagia or respiratory distress was not found. 87% of the patients were independent for basic and daily activities.

    Conclusion: Guillain Barre syndrome related to ZKV infection is a severe disease with a high grade of disabilty at six months after the episode,

    Lina Villa, MD1, Jose Rodriguez, MD2, Jorge Cortes, MD3, Daniela Cala, MD1, Pablo Chaparro, MD, PhD4, Mauricio Beltran, BSc4, Dioselina Pelaez, BSc4, Lissethe Pardo, BSc4, Katherine Laiton, BSc4, Angela Rico, BSc4 and Diego Alvarez, BSc4, (1)Universidad Nacional de Colombia, Bogota, Colombia, (2)Hospital Rosario Pumarejo Lopez, Valledupar, Colombia, (3)Medicine, Universidad Nacional de Colombia, Bogota, Colombia, (4)Instituto Nacional de Salud, Bogota, Colombia

    Disclosures:

    L. Villa, None

    J. Rodriguez, None

    J. Cortes, None

    D. Cala, None

    P. Chaparro, None

    M. Beltran, None

    D. Pelaez, None

    L. Pardo, None

    K. Laiton, None

    A. Rico, None

    D. Alvarez, None

    See more of: Global Infections
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.